Literature DB >> 7864094

Hepatic denervation does not significantly change the response of the liver to glucagon in conscious dogs.

M Wada1, C C Connolly, C Tarumi, D W Neal, A D Cherrington.   

Abstract

In view of the increasing frequency of liver transplantation, and the importance of glucagon in the minute-to-minute regulation of glucose production, we assessed the effect of hepatic denervation on the liver's response to a physiological rise in glucagon in 18-h fasted dogs. Before study (2 wk), the dogs underwent liver denervation (DN; n = 6) or sham operation (SH; n = 5). Endogenous insulin and glucagon secretion were inhibited using somatostatin, and the two hormones were replaced intraportally in basal amounts. After the control period the glucagon infusion rate was tripled for 3 h. Glucagon increased from 41 +/- 8 to 128 +/- 8 and 54 +/- 4 to 129 +/- 9 pg/ml in SH and DN, respectively (P < 0.05), causing tracer-determined glucose production to increase from 2.5 +/- 0.1 to 4.9 +/- 0.5 and 2.3 +/- 0.1 to 5.8 +/- 0.8 mg.kg-1.min-1 by 15 min, respectively (P < 0.05). Glucose clearance fell slightly during glucagon infusion in DN, causing a somewhat greater increase in the plasma glucose level (to 175 +/- 15 vs. 207 +/- 20 mg/dl). The changes in gluconeogenic efficiency increased 65-90% in both groups (P < 0.05). In conclusion, denervation of the liver failed to significantly alter the metabolic response of that organ to a half-maximally effective increment in the plasma glucagon level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7864094     DOI: 10.1152/ajpendo.1995.268.2.E194

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

Authors:  Roger H Unger; Alan D Cherrington
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

2.  Regulation of glucose homeostasis in humans with denervated livers.

Authors:  G Perseghin; E Regalia; A Battezzati; S Vergani; A Pulvirenti; I Terruzzi; D Baratti; F Bozzetti; V Mazzaferro; L Luzi
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension.

Authors:  Carlos Bernal-Mizrachi; Liu Xiaozhong; Li Yin; Russell H Knutsen; Michael J Howard; Joop J A Arends; Pascual Desantis; Trey Coleman; Clay F Semenkovich
Journal:  Cell Metab       Date:  2007-02       Impact factor: 27.287

Review 4.  The physiology of glucagon.

Authors:  Gerald J Taborsky
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

5.  Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs.

Authors:  Tracy P Torres; Noriyasu Sasaki; E Patrick Donahue; Brooks Lacy; Richard L Printz; Alan D Cherrington; Judith L Treadway; Masakazu Shiota
Journal:  J Pharmacol Exp Ther       Date:  2011-03-01       Impact factor: 4.030

Review 6.  Physiologic action of glucagon on liver glucose metabolism.

Authors:  C J Ramnanan; D S Edgerton; G Kraft; A D Cherrington
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

7.  Glucagon's yin and yang effects on hepatic glucose production.

Authors:  Dale S Edgerton; Alan D Cherrington
Journal:  Nat Med       Date:  2013-06       Impact factor: 53.440

8.  Glucose autoregulation is the dominant component of the hormone-independent counterregulatory response to hypoglycemia in the conscious dog.

Authors:  Justin M Gregory; Noelia Rivera; Guillaume Kraft; Jason J Winnick; Ben Farmer; Eric J Allen; E Patrick Donahue; Marta S Smith; Dale S Edgerton; Phillip E Williams; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-16       Impact factor: 4.310

9.  The kinetics of glucagon action on the liver during insulin-induced hypoglycemia.

Authors:  Christina Pedersen; Guillaume Kraft; Dale S Edgerton; Melanie Scott; Ben Farmer; Marta Smith; David C Laneve; Phillip E Williams; L Merkle Moore; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-03-24       Impact factor: 4.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.